Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.

Abstract

AIMS:

To evaluate the cost-effectiveness of standard-of-care treatment (SoC) to SoC in combination with omalizumab (OML + Soc) in patients with severe asthma using real-world prospective clinical data from four major medical centers in Turkey.

MATERIALS AND METHODS:

Between February 2018 and November 2019, a total of 206 patients with severe asthma, including 126 of whom were in the OML + SoC group and 80 in the SoC group, were followed for 12 months to evaluate their asthma status and quality of life. Cost data for this patient-level economic evaluation were sourced from the MEDULA database of the hospitals and expressed in Turkish Lira (₺). Efficacy data were obtained by means of Turkish versions of the Asthma Control Test for asthma status, the 5-level EQ-5D-5L version (EQ-5D-5L), and the Asthma Quality of Life Scale for quality of life. A Markov model with 2-week cycles was specified, comparing costs and treatment effects of SoC vs. OML + SoC over a lifetime from the Turkish payer perspective.

RESULTS:

Per-patient costs were ₺23,607.08 in the SoC arm and ₺425,329.81 in the OML + Soc arm, for a difference of ₺401,722.74. Life years (LY) and quality-adjusted life years (QALY) were 13.60 and 10.08, respectively, in the SoC group; and 21.26 and 13.35, respectively, in the OML + SoC group, for differences of 7.66 LYs and 3.27 QALYs. This yielded an incremental cost-effectiveness ratio of an additional ₺52,427.04 to gain 1 LY and an incremental cost-utility ratio of an incremental ₺122,675.57 to gain 1 QALY; the latter being below the ₺156,948 willingness-to-pay threshold for Turkey referenced by WHO. One-way and multivariate sensitivity analyses confirmed the base-case results.

CONCLUSION:

Whereas most economic evaluations are based on aggregate data, this independent cost-effectiveness analysis using prospective real-world patient-level data suggests that omalizumab in combination with standard of care is cost-effective for severe asthma from the Turkish public payer perspective.

• Authors: Deniz Tugay, Mehmet Top, Ömür Aydin, Sevim Bavbek, Ebru Damadoğlu, Ferda Öner Erkekol, Ilkay Koca Kalkan, A Fuat Kalyoncu, Gül Karakaya, I Kivilcim Oğuzülgen, Haluk Türktaş, Ivo Abraham
• Journal: Journal of medical economics (J Med Econ) 2023 Jan-Dec Vol. 26 Issue 1 Pg. 720-730 ISSN: 1941-837X [Electronic] England
• PMID: 37129881 (Publication Type: Journal Article)

Chemical References

• Omalizumab

Topics

• Humans
• Omalizumab
• Cost-Effectiveness Analysis
• Quality of Life
• Prospective Studies
• Turkey
• Asthma (drug therapy)
• Cost-Benefit Analysis
• Hospitals
• Quality-Adjusted Life Years